Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer

References

• Jemal A , SiegelR , XuJ , WardE . Cancer statistics, 2010 . CA Cancer J. Clin.60 ( 5 ), 277 – 300 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Goldberg RM . Therapy for metastatic colorectal cancer . Oncologist11 ( 9 ), 981 – 987 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P , LievreA , BlonsH . Mutations and response to epidermal growth factor receptor inhibitors . Clin. Cancer Res.15 ( 4 ), 1133 – 1139 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY , SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer . N. Engl. J. Med.351 ( 4 ), 337 – 345 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Jonker DJ , O’CallaghanCJ , KarapetisCSet al. Cetuximab for the treatment of colorectal cancer . N. Engl. J. Med.357 ( 20 ), 2040 – 2048 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , PeetersM , SienaSet al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer . J. Clin. Oncol.25 ( 13 ), 1658 – 1664 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI , MakhsonAet al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer . J. Clin. Oncol.27 ( 5 ), 663 – 671 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneCH , HitreEet al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer . N. Engl. J. Med.360 ( 14 ), 1408 – 1417 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Douillard JY , SienaS , CassidyJet al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study . J. Clin. Oncol.28 ( 31 ), 4697 – 4705 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lièvre A , BachetJB , Le CorreDet al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer . Cancer Res.66 ( 8 ), 3992 – 3995 ( 2006 ). 
   PubMed Web of Science ®Google Scholar
• Scaltriti M , BaselgaJ . The epidermal growth factor receptor pathway: a model for targeted therapy . Clin. Cancer Res.12 ( 18 ), 5268 – 5272 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lièvre A , BachetJB , BoigeVet al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab . J. Clin. Oncol.26 ( 3 ), 374 – 379 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Vaughn CP , ZobellSD , FurtadoLV , BakerCL , SamowitzWS . Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer . Genes Chromosomes Cancer50 ( 5 ), 307 – 312 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network . Comprehensive molecular characterization of human colon and rectal cancer . Nature487 ( 7407 ), 330 – 337 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• De Roock W , JonkerDJ , Di NicolantonioFet al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab . JAMA304 ( 16 ), 1812 – 1820 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Peeters M , DouillardJY , Van CutsemEet al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab . J. Clin. Oncol.31 ( 6 ), 759 – 765 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• André T , BlonsH , MabroMet al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study . Ann. Oncol.24 ( 2 ), 412 – 419 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Peeters M , OlinerKS , ParkerAet al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized Phase III study of metastatic colorectal cancer . Clin. Cancer Res.19 ( 7 ), 1902 – 1912 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Douillard JY , OlinerKS , SienaSet al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer . N. Engl. J. Med.369 ( 11 ), 1023 – 1034 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Stintzing S , JungA , RossiusLet al. Analysis of KRAS/NRAS and BRAF Mutations in FIRE-3: a Randomized Phase III Study of FOLFIRI plus Cetuximab or Bevacizumab as First-Line Treatment for Wild-Type (WT) KRAS (exon 2) Metastatic Colorectal Cancer (mCRC) Patients. Presented at: The European Cancer Congress 2013 . Amsterdam, The Netherlands , 27 September–1 October 2013 . 
   Google Scholar
• Van Cutsem E , KöhneCH , LángIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J. Clin. Oncol.29 ( 15 ), 2011 – 2019 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Modrek B , GeL , PanditaAet al. Oncogenic activating mutations are associated with local copy gain . Mol. Cancer Res.7 ( 8 ), 1244 – 1252 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Smith G , BoundsR , WolfH , SteeleRJ , CareyFA , WolfCR . Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine . Br. J. Cancer102 ( 4 ), 693 – 703 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Valtorta E , MisaleS , Sartore-BianchiAet al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy . Int. J. Cancer133 ( 5 ), 1259 – 1265 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Soh J , OkumuraN , LockwoodWWet al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells . PLoS ONE4 ( 10 ), e7464 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Hartman DJ , DavisonJM , FoxwellTJ , NikiforovaMN , ChioseaSI . Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival . Int. J. Cancer131 ( 8 ), 1810 – 1817 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mekenkamp LJ , TolJ , DijkstraJRet al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients . BMC Cancer12 , 292 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Samuels Y , WangZ , BardelliAet al. High frequency of mutations of the PIK3CA gene in human cancers . Science304 ( 5670 ), 554 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Bhaskar PT , HayN . The two TORCs and Akt . Dev. Cell12 ( 4 ), 487 – 502 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Cully M , YouH , LevineAJ , MakTW . Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis . Nat. Rev. Cancer6 ( 3 ), 184 – 192 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB , BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis . Lancet Oncol.11 ( 8 ), 753 – 762 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Soeda H , ShimodairaH , WatanabeMet al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer . Int. J. Clin. Oncol.18 ( 4 ), 670 – 677 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mao C , YangZY , HuXF , ChenQ , TangJL . PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis . Ann. Oncol.23 ( 6 ), 1518 – 1525 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sood A , McClainD , MaitraRet al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer . Clin. Colorectal Cancer11 ( 2 ), 143 – 150 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Li FH , ShenL , LiZHet al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer . World J. Gastroenterol.16 ( 46 ), 5881 – 5888 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tural D , BaturS , ErdamarSet al. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS . Tumour Biol.35 ( 2 ), 1041 – 1049 ( 2013 ).
   PubMedGoogle Scholar
• Karapetis CS , JonkerD , DaneshmandMet al. PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from NCIC CTG/AGITG CO.17 . Clin. Cancer Res.20 ( 3 ), 744 – 753 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Perkins G , LièvreA , RamacciCet al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer . Int. J. Cancer127 ( 6 ), 1321 – 1331 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Comoglio PM , GiordanoS , TrusolinoL . Drug development of MET inhibitors: targeting oncogene addiction and expedience . Nat. Rev. Drug Discov.7 ( 6 ), 504 – 516 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zeng ZS , WeiserMR , KuntzEet al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases . Cancer Lett.265 ( 2 ), 258 – 269 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Bardelli A , CorsoS , BertottiAet al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer . Cancer Discov.3 ( 6 ), 658 – 673 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Liska D , ChenCT , Bachleitner-HofmannT , ChristensenJG , WeiserMR . HGF rescues colorectal cancer cells from EGFR inhibition via MET activation . Clin. Cancer Res.17 ( 3 ), 472 – 482 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Krumbach R , SchülerJ , HofmannM , GiesemannT , FiebigHH , BeckersT . Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance . Eur. J. Cancer47 ( 8 ), 1231 – 1243 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Troiani T , MartinelliE , NapolitanoSet al. Increased TGF-α as a mechanism of acquired resistance to the Anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells . Clin. Cancer Res.19 ( 24 ), 6751 – 6765 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nicholson RI , GeeJM , HarperME . EGFR and cancer prognosis . Eur. J. Cancer37 ( Suppl. 4 ), S9 – S15 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Goldstein NS , ArminM . Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system . Cancer92 ( 5 ), 1331 – 1346 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Chung KY , ShiaJ , KemenyNEet al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry . J. Clin. Oncol.23 ( 9 ), 1803 – 1810 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hebbar M , WacrenierA , DesauwCet al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer . Anticancer Drugs17 ( 7 ), 855 – 857 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Moroni M , VeroneseS , BenvenutiSet al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study . Lancet Oncol.6 ( 5 ), 279 – 286 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P , CayreA , ManceauGet al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer . J. Clin. Oncol.27 ( 35 ), 5924 – 5930 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ålgars A , LintunenM , CarpénO , RistamäkiR , SundströmJ . EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer . Br. J. Cancer105 ( 2 ), 255 – 262 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lenz HJ , Van CutsemE , Khambata-FordSet al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines . J. Clin. Oncol.24 ( 30 ), 4914 – 4921 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Italiano A , FollanaP , CaroliFXet al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number . Ann. Surg. Oncol.15 ( 2 ), 649 – 654 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Yang ZY , ShenWX , HuXFet al. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis . J. Hematol. Oncol.5 , 52 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Barber TD , VogelsteinB , KinzlerKW , VelculescuVE . Somatic mutations of EGFR in colorectal cancers and glioblastomas . N. Engl. J. Med.351 ( 27 ), 2883 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Vallböhmer D , ZhangW , GordonMet al. Molecular determinants of cetuximab efficacy . J. Clin. Oncol.23 ( 15 ), 3536 – 3544 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Montagut C , DalmasesA , BellosilloBet al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer . Nat. Med.18 ( 2 ), 221 – 223 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S , GarrettCR , MeropolNJet al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab . J. Clin. Oncol.25 ( 22 ), 3230 – 3237 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Jacobs B , De RoockW , PiessevauxHet al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab . J. Clin. Oncol.27 ( 30 ), 5068 – 5074 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Jonker DJ , KarapetisCS , HarbisonCet al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer . Br. J. Cancer110 , 648 – 655 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Saridaki Z , TzardiM , PapadakiCet al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients . PLoS ONE6 ( 1 ), e15980 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G , KotoulaV , De RoockWet al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes . BMC Cancer13 , 49 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ooi A , TakehanaT , LiXet al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study . Mod. Pathol.17 ( 8 ), 895 – 904 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Martin V , LandiL , MolinariFet al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients . Br. J. Cancer108 ( 3 ), 668 – 675 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bertotti A , MigliardiG , GalimiFet al. A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer . Cancer Discov.1 ( 6 ), 508 – 523 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Yonesaka K , ZejnullahuK , OkamotoIet al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab . Sci. Transl. Med.3 ( 99 ), 99ra86 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK , HwangJJ , ZamboniWCet al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A Phase II trial . Cancer Invest.22 ( 6 ), 858 – 865 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Lédel F , HallströmM , RagnhammarP , OhrlingK , EdlerD . HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome . Eur. J. Cancer50 ( 3 ), 656 – 662 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Scartozzi M , GiampieriR , MaccaroniEet al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab . Ann. Oncol.23 ( 7 ), 1706 – 1712 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wheeler DL , HuangS , KruserTJet al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members . Oncogene27 ( 28 ), 3944 – 3956 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Shuptrine CW , SuranaR , WeinerLM . Monoclonal antibodies for the treatment of cancer . Semin. Cancer Biol.22 ( 1 ), 3 – 13 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y , KonoK , MimuraK , SugaiH , AkaikeH , FujiiH . Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma . Int. J. Cancer120 ( 4 ), 781 – 787 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hara M , NakanishiH , TsujimuraKet al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity . Cancer Sci.99 ( 7 ), 1471 – 1478 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Correale P , MarraM , RemondoCet al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) . Eur. J. Cancer46 ( 9 ), 1703 – 1711 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zhang W , GordonM , SchultheisAMet al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab . J. Clin. Oncol.25 ( 24 ), 3712 – 3718 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bibeau F , Lopez-CrapezE , Di FioreFet al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan . J. Clin. Oncol.27 ( 7 ), 1122 – 1129 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Rodríguez J , ZarateR , BandresEet al. Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer . Eur. J. Cancer48 ( 12 ), 1774 – 1780 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Paez D , ParéL , EspinosaIet al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci. 101 ( 9 ), 2048 – 2053 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Park SJ , HongYS , LeeJLet al. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer . Oncology82 ( 2 ), 83 – 89 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Negri FV , MusolinoA , NaldiNet al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy . Pharmacogenomics J.14 ( 1 ), 14 – 19 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nakadate Y , KoderaY , KitamuraYet al. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells . Int. J. Cancer134 ( 9 ), 2146 – 2155 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kasper S , BreitenbuecherF , ReisHet al. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade . Oncogene32 ( 23 ), 2873 – 2881 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gomez GG , WykoskyJ , ZancaC , FurnariFB , CaveneeWK . Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks . Cancer Biol. Med.10 ( 4 ), 192 – 205 ( 2013 ).
   PubMedGoogle Scholar
• Mlcochova J , FaltejskovaP , NemecekR , SvobodaM , SlabyO . MicroRNAs targeting EGFR signalling pathway in colorectal cancer . J. Cancer Res. Clin. Oncol.139 ( 10 ), 1615 – 1624 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ruzzo A , GrazianoF , VincenziBet al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease . Oncologist17 ( 6 ), 823 – 829 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Graziano F , CanestrariE , LoupakisFet al. Genetic modulation of the Let-7 microRNA binding to KRAS 3’-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan . Pharmacogenomics J. 10 ( 5 ), 458 – 464 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kjersem JB , IkdahlT , GurenTet al. Let-7 miRNA-binding site polymorphism in the KRAS 3’UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab . BMC Cancer12 , 534 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhang W , WinderT , NingYet al. A let-7 microRNA-binding site polymorphism in 3’-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy . Ann. Oncol.22 ( 1 ), 104 – 109 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Pichler M , WinterE , StotzMet al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer . Br. J. Cancer106 ( 11 ), 1826 – 1832 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nosho K , IgarashiH , NojimaMet al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway . Carcinogenesis35 ( 4 ), 776 – 783 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mosakhani N , LahtiL , BorzeIet al. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF . Cancer Genet.205 ( 11 ), 545 – 551 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Manceau G , ImbeaudS , MosakhaniNet al. Hsa-miR-31–3p Expression in FFPE Tumor Samples as a Predictor of Anti-EGFR Response in Patients with Metastatic Colorectal Cancer (mCRC). Presented at: The European Cancer Congress 2013 . Amsterdam, The Netherlands , 27 September–1 October 2013 .
   Google Scholar
• Pichler M , WinterE , RessALet al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor . J. Clin. Pathol.67 ( 3 ), 198 – 203 ( 2013 ).
   PubMed Web of Science ®Google Scholar